Collins P, Sheridan D
Br Heart J. 1985 May;53(5):488-92. doi: 10.1136/hrt.53.5.488.
The effects of indoramin, a selective alpha 1 adrenoceptor antagonist, on exercise tolerance were studied in 15 patients using a random double blind crossover protocol. All patients had chronic stable angina, for which 13 had been receiving beta adrenoceptor blocking drugs and nitrates, and these were continued unchanged throughout the study. An initial open challenge with indoramin in eight patients with chronic stable angina showed no serious adverse effects. In a dose of 25 mg three times daily indoramin prolonged exercise duration and increased oxygen consumption during exercise, while the maximal double product was unchanged. The increased exercise capacity was associated with a reduction in ST segment depression during exercise. Side effects included failure of ejaculation in one patient and tiredness in five. These results indicate than alpha 1 adrenoceptor blockade may provide useful additional benefit to patients with stable angina pectoris who are already receiving beta blockers and nitrates.
采用随机双盲交叉试验方案,对15例患者研究了选择性α1肾上腺素能受体拮抗剂吲哚拉明对运动耐量的影响。所有患者均患有慢性稳定性心绞痛,其中13例一直在接受β肾上腺素能受体阻滞剂和硝酸盐治疗,且在整个研究过程中持续用药不变。对8例慢性稳定性心绞痛患者进行的初始开放性吲哚拉明激发试验未显示严重不良反应。吲哚拉明每日3次,每次25mg,可延长运动持续时间,并增加运动期间的耗氧量,而最大心率收缩压乘积不变。运动能力的提高与运动期间ST段压低的减轻有关。副作用包括1例患者射精障碍和5例患者疲劳。这些结果表明,α1肾上腺素能受体阻滞可能为已接受β受体阻滞剂和硝酸盐治疗的稳定型心绞痛患者提供有益的额外益处。